<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855191</url>
  </required_header>
  <id_info>
    <org_study_id>SDC Lung</org_study_id>
    <nct_id>NCT01855191</nct_id>
  </id_info>
  <brief_title>SDC for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation</brief_title>
  <acronym>SDC lung</acronym>
  <official_title>Standardized Data Collection (SDC) for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation (SDC Lung).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introducing standardized data collection (SDC) for lung cancer patients to improve the
      performance of the prediction models.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients planned for curative primary or postoperative radiotherapy can be included.
      Patients will be treated according to the institutional protocol. It is optional to collect a
      saliva sample for genetic profiling.

      Follow up at five time points:

        -  2 weeks after RT

        -  3 months after RT

        -  6 months after RT

        -  12 months after RT

        -  24 months after RT

      At these time points, toxicity will be assessed. In addition, patients will receive a short
      questionnaire by mail at eight time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year survival rate</measure>
    <time_frame>24 months after RT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnea</measure>
    <time_frame>during 24 months after RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cough</measure>
    <time_frame>During 24 months after RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dysphagia</measure>
    <time_frame>During 24 months after RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-rated generic quality of life</measure>
    <time_frame>During 24 months after RT</time_frame>
    <description>Measured by Euroqol questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">864</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard + saliva collection</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients planned for curatively intended radiotherapy or postoperative radiotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients planned for curatively intended radiotherapy or postoperative
             radiotherapy

          -  Recurrent disease

        Exclusion Criteria:

          -  All patients planned for palliative radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

